127 related articles for article (PubMed ID: 28121747)
1. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
3. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
4. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
5. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
8. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
9. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
10. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
12. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
Ansari SH; Hussain Z; Zohaib M; Parveen S; Kaleem B; Qamar H; Adil O; Khan MT; Shamsi TS
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e77-e83. PubMed ID: 33710118
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
16. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
[TBL] [Abstract][Full Text] [Related]
17. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
18. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
19. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]